Google Groups no longer supports new Usenet posts or subscriptions. Historical content remains viewable.
Dismiss

Medicines in development in 2009 for prostate cancers

0 views
Skip to first unread message

SciMedWeb

unread,
Dec 22, 2009, 5:16:43 AM12/22/09
to
Medicines in development in 2009 for prostate cancers:

● ABI-008 Phase I/II
● abiraterone acetate (CB7630) Phase III
● ABR-215050 Phase II
● Abraxane (albumin-bound paclitaxel) Phase II
● Acapodene (toremifene) Phase III
● Actimid (pomalidomide) Phase II
● Advexin (contusugene ladenovec) Phase I
● aflibercept (VEGF-trap) Phase III
● AGS-1C4D4 Phase I
● Amplimexon (imexon) Phase I
● anti-idiotype cancer vaccine 105AD7 Phase II
● AT-101 Phase II
● ATN-224 Phase II
● Avastin (bevacizumab) Phase III
● Avodart (dutasteride) Phase III
● AZD4054 Phase III
● BMS-641988 (androgen receptor antagonist)Phase I
● cabazitaxel (XRP6258) Phase III
● Camptosar (irinotecan) Phase II
● Celebrex (celecoxib) Phase II
● cilengitide Phase II
● CNTO 95 Phase II
● CNTO 328 Phase II
● CP-751871 Phase II
● CYT-500 Phase I
● deforolimus (MK-8669) Phase II
● DMXAA Phase II
● enzastaurin (LY317615) Phase II
● Erbitux (cetuximab) Phase III
● eribulin mesylate (E7389) Phase II
● Gleevec (imatinib) Phase II/III
● GRNVAC1 Phase I/II
● GTx-758 Phase I
● HE-3235 Phase I/II
● Herceptin (trastuzumab) Phase II
● Hycamtin (topotecan) Phase II
● HyperAcute (prostate cancer vaccine) Phase I/II
● idronoxil Phase II
● IMC-1121B Phase II
● IMC-A12 Phase II
● INCB-18424 Phase II
● INSM-18 Phase I/II
● Ixempra (ixabepilone)
● JNJ-26854165 Phase I
● Leukine (sargramostim) Phase II
● Leupron (leuprorelin depot) Phase III
● leuprorelin inhalation Phase I
● MCS110 Phase I/II
● MDV-3100 Phase I/II
● mepacrine Phase II
● MER-104 Phase I/II
● MIP1072 Phase I
● MIP1095 Phase I
● MK-0429 Phase I
● MVA-BN-PRO Phase I/II
● NBI-42902 Phase I
● NeuVax (E75 cancer vaccine) Phase I/II
● OGX-427 Phase I
● Oncolar (octreotide) Phase II
● ONY-105 (cancer vaccine) Phase II
● ONY-P (prostate cancer vaccine) Phase II
● ozarelix Phase I/II
● panobinostat Phase II
● plitidepsin Phase II
● polyphenon E Phase II
● Proscar (finasteride) Phase III
● ProstAtak (gene therapy) Phase II
● Prostvac-VF (prostate cancer vaccine) Phase II
● Provenge (sipuleucel-T)
● PRX-302 Phase II
● PSMA-ADC Phase I
● PSMA cancer vaccine Phase I
● Quadramet (samarium SM-153 lexidronam injection) Phase II
● Quinamed (amonafide) Phase II
● Revlimid (lenalidomide) Phase II
● romidepsin Phase II
● sagopilone Phase II
● satraplatin Phase III
● seocalcitol (CB1089) Phase I
● Sprycel (dasatinib)
● Sutent (sunitinib) Phase III
● TAK683 Phase I
● TAK700 Phase I/II
● tandutinib (MLN0518) Phase II
● tesmilifene Phase II
● TheraCIM (nimotuzumab) Phase II
● Thymitaq (nolatrexed) Phase II
● tigapotide Phase II
● Torisel (temsirolimus) Phase II
● TPI-287 Phase II
● transgenic B (lymphocyte immunotherapy/cancer vaccine) Phase II
● tremelimumab Phase II
● Triapine Phase II
● trilostane Phase II
● tucotuzumab (celmoleukin) Phase II
● VDC2008 Phase I/II
● Vidaza (azacitidine) Phase II
● VP101 Phase II
● YM-155 Phase II
● YMB2002 (prostate cancer vaccine) Phase II
● Yondelis (trabectedin) Phase II
● ZYC300 Phase I

InTextoResearch, Baelen, Liège, Wallonie (Wallonia), Belgique
(Belgium) & Agence Wallonne d’Information Scientifique (AWIS) (Marc
Lacroix, scim...@mail.com)

0 new messages